Did ClearPoint Neuro beat or miss consensus estimates last quarter?

What were the key takeaways from ClearPoint Neuro's earnings call?

What does ClearPoint Neuro do and what are its main business segments?

What were the key takeaways from ClearPoint Neuro’s earnings call?

What is ClearPoint Neuro's latest dividend and current dividend yield?

What factors drove the changes in ClearPoint Neuro's revenue and profit?

What guidance did ClearPoint Neuro's management provide for the next earnings period?

What is the market's earnings forecast for ClearPoint Neuro next quarter?

- **2025 Revenue Growth**: 18% YoY to $37 million, driven by biologics/drug delivery (+10%) and navigation (+33%).
- **2026 Guidance**: $52-56 million, excluding rare disease approvals; 4 segments to grow double digits.
- **Strategic Shifts**: Tightened guidance due to FDA Phase III requirements, IRRAS European market reset.
- **Key Risks**: Regulatory delays, integration challenges, reliance on biopharma partners.
- **Growth Drivers**: 60+ biopharma partners, 25+ clinical trials, $500M neurocritical care market entry.

**【CEO Opening Remarks】**
- **2025 Revenue**: $37 million (up 18% YoY from $31.4 million), driven by biologics/drug delivery (+10%), neurosurgery navigation (+33%), and capital equipment.
- **Acquisition of IRRAS**: Added $1.2 million in Q4 revenue, expanding neurocritical care capabilities.
- **2026 Guidance**: Revenue $52-56 million, excluding potential rare disease approvals.
- **Strategic Phases**: 
  1. **Fast Forward**: Penetrate existing $1 billion market across 4 segments (biologics, navigation, laser, neurocritical) with double-digit growth.
  2. **Essential Everywhere**: Build new market for cell/gene therapy delivery, supported by 60+ biopharma partners and 25+ clinical trials.

**【CFO Financial Commentary】**
- **Q4 2025 Results**: Revenue $10.4 million (up 33% YoY), gross margin 62%, operating expenses $13.4 million (up 30% YoY due to IRRAS integration).
- **Full Year 2025**: 
  - R&D/Sales & Marketing: $13.9M (+12%), $16.5M (+14%) due to headcount expansion.
  - G&A: $16.5M (+38%) driven by IRRAS costs and severance.
  - Cash: $45.9M (up from $20.1M) from $51.4M debt issuance, offset by $23.9M operating cash use.

**【CEO Detailed Strategy】**
- **4 Growth Pillars (2026 double-digit growth)**:
  1. **Biologics/Drug Delivery**: $19M in 2025, expanding with GLP lab and 60+ partners.
  2. **Navigation & Robotics**: 3.x software adoption, robotic platform development, Japan PMDA filing.
  3. **Laser Therapy**: PRISM 1.5T MRI clearance, Velocity MR drill launch.
  4. **Neurocritical Care**: IRRAS catheter integration, ARCH trial data expected.
- **Risks**: FDA requiring Phase III trials for rare diseases delays commercialization, IRRAS European market reset.

**【Q&A Highlights】**
- **2026 Guidance Tightening**: Removed rare disease launch assumptions, adjusted IRRAS European strategy.
- **Organic vs. Inorganic Growth**: Balanced 15-20% growth from both, e.g., $15-20M GLP studies, IRRAflow market share gains.
- **Diversification**: 10+ partners in FDA expedited review (Parkinson's, epilepsy, glioma), reducing uniQure dependency.
- **PRISM Expansion**: Tumor clinical trial data publication to expand neuro-oncology use case.

ClearPoint Neuro, Inc.(CLPT)-20260318-2025 Q4 Earnings call transcript

- **$500M Neurocritical Care Expansion**: Acquired IRRAS to enter $500M+ intracranial fluid management market with 83% YoY growth and <5% share.
- **$8.9M Q3 Revenue**: 9% YoY growth driven by 20% neurosurgery navigation and 25% capital equipment sales.
- **2026 Guidance**: $54-60M revenue (post-merger), targeting 70%+ gross margin through scale.
- **CRO Facility Potential**: New facility enables $5-10M+ studies, with GLP services adding $10M+ annual revenue.
- **Cell/Gene Therapy Pipeline**: Supporting 20+ indications, including 7 under FDA expedited review, with 2.1M U.S. patients eligible.

**【CEO Opening Remarks】**
- Announced merger with IRRAS, a leader in neurocritical care, to expand into a $500M+ market for intracranial fluid management. The deal includes $5M cash and 1.325M shares, with closing expected in Q4 2025.
- Introduced 2 strategic phases: 
  1. **Fast Forward**: Penetrate existing $1B+ market across 4 pillars (biologics/drug delivery, neurosurgery navigation, laser therapy, irrigation/aspiration) with <5% share.
  2. **Essential Everywhere**: Build a new $10B+ market for neuro drug delivery with biopharma partners.
- Highlighted IRRAS' 83% YoY growth and $9M run rate, with 40+ new commercial team members to be integrated.

**【CFO Financial Commentary】**
- Q3 2025 revenue: $8.9M (+9% YoY), driven by 20% growth in neurosurgery navigation and 25% in capital equipment.
- Gross margin: 63% (vs. 60% YoY), up due to higher service revenue mix.
- R&D/S&M/G&A expenses increased 4%/8%/14% YoY, reflecting headcount expansion.
- Cash: $38.2M (vs. $20.1M at year-end 2024), supported by $32M in financing.
- 2025 full-year revenue guidance: $36-38M; 2026 pro forma revenue: $54-60M post-merger.

**【CEO Strategic Update】**
- **4 Pillar Growth Strategy**:
  1. **Pre-Commercial Biologics**: $300M market with <10% share; new CRO facility in Torrey Pines to support larger studies.
  2. **Neurosurgery Navigation & Robotics**: $125M market; launching 3.0 software, DUET Frame, and robotic platform.
  3. **Laser Therapy & Access**: $75M market; full release of PRISM system with 1.5T MRI compatibility.
  4. **Cranial Irrigation & Aspiration**: $500M market; IRRAS' IRRAflow system has <5% share but 83% YoY growth.
- **Cell/Gene Therapy Pipeline**: Supporting 20+ indications across 60+ biopharma partners, including 7 under FDA expedited review (e.g., AADC deficiency, Huntington's disease).
- 2026 revenue guidance: $54-60M (includes IRRAS), with >20% CAGR potential through market share gains.

**【Q&A Highlights】**
- **Neurocritical Care Market**: 400K+ annual procedures in the U.S., with IRRAS' IRRAflow system offering active irrigation/aspiration to reduce clogs and hospital costs. Competes with legacy EVD systems lacking innovation.
- **2026 Revenue Breakdown**: ~$36M from ClearPoint, $18M from IRRAS (post-merger). Gross margin target: 70%+ as scale is achieved.
- **CRO Facility Impact**: New facility enables $5-10M+ studies vs. prior max of $2M. GLP studies and expanded services (e.g., histology) could add $10M+ annual revenue.
- **Burn Rate**: Mid-single-digit millions in 2026, declining as revenue grows. Integration costs limited to Q4 2025-Q1 2026.

ClearPoint Neuro, Inc. (CLPT) Q3 2025 Earnings Call Transcript

- **Revenue Growth**: Q2 2025 revenue up 17% YoY to $9.2M, driven by 33% jump in neurosurgery navigation sales.
- **Strategic Milestones**: 9 FDA expedited programs, first U.S. commercial neuro therapy cases, 17 global infusions in July.
- **Product Innovation**: 3.0 navigation software achieves 2-hour DBS procedures, PRISM Laser gains 5-10% market share.
- **Global Expansion**: 36 regulatory clearances, 15-20 new site activations expected in 2025.
- **Financial Strength**: $41.5M cash, $32M Oberland Capital financing, stable operational cash burn.

**【CEO Summary Section】**
- Introduced the 'Fast. Forward.' strategy with 3 tenets: extending lead in cell/gene therapy, evolving portfolio for efficiency, and global expansion. 
- Highlighted 60+ biopharma partners progressing through FDA expedited reviews (9 programs now in expedited track). 
- Announced first U.S. commercial neuro cell/gene therapy cases and 17 global infusions in July across 11 platforms.
- Expanded preclinical facility in Torrey Pines, CA, set to open late 2025 with GLP capabilities.
- 3.0 navigation software deployed in 35 sites, achieving 2-hour bilateral DBS procedures with <1mm radial error.
- PRISM Laser Therapy system gains 5-10% U.S. market share, targeting 1.5T MRI compatibility in H2 2025.
- Activated 2 new sites in Q2, on track for 15-20 new activations in 2025, with 36 global regulatory clearances.

**【CFO Financial Commentary】**
- Q2 2025 revenue: $9.2M (+17% YoY), driven by:
  - Biologics/drug delivery: $4.7M (+10%)
  - Neurosurgery navigation: $3.4M (+33%)
  - Capital equip/software: $1M (+11%)
- Gross margin: 60% (vs 63% YoY), down due to inventory reserves.
- Operating expenses: $11.2M (+16% YoY) from R&D (+23%), sales/marketing (+5%).
- Cash position: $41.5M (vs $20.1M at year-end), with $32M from Oberland Capital financing.
- Operational cash burn: $2.6M (stable vs Q2 2024).

ClearPoint Neuro, Inc. (CLPT) Q2 2025 Earnings Call Transcript

- **Strategic Acceleration**: Entered 'Fast Forward' phase with $32M Oberland Capital backing, focusing on cell/gene therapy, workflow efficiency, and global expansion.
- **Revenue Growth**: Q1 2025 revenue $8.5M (+11% YoY), driven by 70% neurosurgery navigation growth and 9% biologics expansion.
- **Product Momentum**: 3.0 navigation software adoption across 11 surgeons (35 cases), PRISM Laser 1.5T MRI compatibility pending, and 104% single-use consumables surge.
- **Operational Investment**: 29% R&D increase for preclinical GLP capabilities, field support hiring, and new product development.
- **Financial Flexibility**: $32M credit facility provides long-term growth runway, with no immediate breakeven pressure.

**【CEO Opening Remarks】**
- Announced entry into the 'Fast Forward' phase with three strategic tenets: extending leadership in cell and gene therapy, evolving product workflows for efficiency, and expanding global install base.
- Highlighted the importance of the ClearPoint ecosystem (hardware, software, services) in supporting 60+ biopharma partners, including those with FDA expedited reviews.
- Emphasized the significance of the $32 million credit facility with Oberland Capital, providing flexibility for long-term growth.

**【CFO Financial Commentary】**
- Q1 2025 total revenue: $8.5 million (11% YoY growth).
- Biologics & Drug Delivery: $4.7 million (+9%), driven by product revenue growth offset by service decline.
- Neurosurgery Navigation: $3.3 million (+70%), fueled by new product launches (e.g., SmartFrame OR, 3.0 software).
- Capital Equipment & Software: $0.5 million (-63%), due to strategic shift to Pathfinder subscriptions.
- Gross margin: 60% (up 1% YoY).
- R&D expenses: $3.4 million (+29%), reflecting investment in product innovation.
- Cash balance: $12.4 million (excluding $32M Oberland proceeds).

**【CEO Detailed Commentary】**
- **Biologics & Drug Delivery**: 60+ active partners, 1.2M increase in product revenue, FDA 510(k) submission for SmartFlow cannula with RGX-121 gene therapy.
- **Neurosurgery Navigation**: 70% growth in single-use consumables, 3.0 software adoption across 11 surgeons (35 cases), average procedure time <2 hours.
- **Laser Ablation**: PRISM Laser revenue growth, 1.5T MRI compatibility submission, 70% market share with 3.0T scanners.
- **Global Scale**: 2 new site activations, 4 Pathfinder subscriptions (deferred revenue recognition), 15-20 expected activations for 2025.
- **Operational Investment**: Hiring preclinical team, field support, and expanding GLP capabilities for 2025H2 readiness.

**【Q&A Highlights】**
- **Capital Utilization**: Accelerating preclinical services, field support hiring, and product development; debt flexibility supports long-term growth without breakeven pressure.
- **Neurosurgery Trajectory**: 70% Q1 growth on track for >20% annual growth; 3.0 software adoption momentum may drive upside.
- **MRI vs OR Procedures**: Strategy to free MRI capacity for drug delivery by shifting DBS to OR; 3.0 software enables OR efficiency without sacrificing accuracy.
- **GLP Certification**: Expected 2025H2 completion; pent-up demand from 5+ pharma partners for expanded preclinical services.
- **OpEx Growth**: 29% YoY driven by R&D and commercial investments; expect revenue growth to outpace expenses for full year.

ClearPoint Neuro, Inc. (CLPT) Q1 2025 Earnings Call Transcript

- **31% Revenue Growth**: 2024 revenue reached $31.4M, driven by biologics (+27%) and capital equipment (+107%).
- **61% Gross Margin**: Improved efficiency and scale reduce costs, with 2025 targeting 70%+ margins.
- **$36-41M 2025 Guidance**: New products and GLP expansion fuel 15%-31% growth.
- **$250M+ Potential**: Biopharma partners' expedited approvals could add $250M+ in cell/gene therapy revenue.
- **Global Scale**: 15-20 new sites in 2025, aiming for 300+ global centers to support $200M neurosurgery market.

**【CEO Opening Remarks】**
- **Fast. Forward Strategy**: Transitioning to a scalable business with three commitments: expanding cell/gene therapy delivery, evolving product workflows for efficiency, and global expansion. 
- **Essential. Everywhere Vision**: Becoming an indispensable partner for hospitals and biopharma, with 60+ active pharma collaborations and 100+ activated centers globally.

**【CFO Financial Highlights】**
- **2024 Revenue**: $31.4M (+31% YoY), driven by biologics (+27%), neurosurgery (+21%), and capital equipment (+107%).
- **Gross Margin**: 61% (vs. 57% 2023), improved due to new manufacturing efficiency and scale.
- **Cash Position**: $20.1M at year-end, after $16.2M equity raise, achieving $9M operational cash burn (-35% YoY).

**【2025 Growth Strategy】**
- **Revenue Guidance**: $36-41M (+15%-31%), with upside from GLP expansion and new product launches.
- **Product Launches**: ClearPoint 3.0 OR navigation, Prism 3.0 laser, Velocity Alpha drill targeting $200M neurosurgery market.
- **Market Opportunity**: $300M preclinical services market (10% penetration) and multi-billion cell/gene therapy market.

**【Q&A Key Takeaways】**
- **Partnership Momentum**: 10+ clinical studies initiated in 2024, potential drug approvals in next 2 years with $250M+ revenue impact.
- **Global Expansion**: 15-20 new sites in 2025, targeting 300+ global centers for scalable workflows.
- **Cash Discipline**: 2025 burn expected below 2024 levels, with cautious investment in high-ROI initiatives.

Actual			-0.13	-0.11	-0.09	-0.09	-0.13	-0.17	-0.18	-0.21	-0.17	-0.18	-0.15	-0.18	-0.23	-0.29	-0.2	-0.18	-0.16	-0.16	-0.18	-0.2	-0.22	-0.21	-0.21	-0.26
Forecast			-0.18	-0.16	-0.14	-0.13	-0.145	-0.135	-0.16	-0.19	-0.2	-0.1852	-0.19	-0.2	-0.19	-0.19	-0.25	-0.2033	-0.19	-0.1967	-0.1733	-0.1639	-0.1587	-0.2	-0.205	-0.2
Surprise	0.00%	0.00%	+27.78%	+31.25%	+35.71%	+30.77%	+10.34%	-25.93%	-12.50%	-10.53%	+15.00%	+2.81%	+21.05%	+10.00%	-21.05%	-52.63%	+20.00%	+11.46%	+15.79%	+18.66%	-3.87%	-22.03%	-38.63%	-5.00%	-2.44%	-30.00%

CLPT

CLPT fundamentals

CLPT Q4 2025 Earnings

Earnings Call

You can ask Aime

CLPT

CLPT fundamentals

CLPT Q4 2025 Earnings

Earnings Call

CLPT Earnings Call Summary for Q4/20254:30 PM on Mar 17, 2026

CLPT Earnings Call Summary for Q3/20255:00 PM on Nov 6, 2025

CLPT Earnings Call Summary for Q2/20254:30 PM on Aug 12, 2025

CLPT Earnings Call Summary for Q1/20254:30 PM on May 13, 2025

CLPT Earnings Call Summary for Q4/20244:30 PM on Feb 26, 2025

You can ask Aime